Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atropine and DIMS for Myopia Control
NCT06523504Phase 2Recruiting
- Start
- Feb 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of NVK002 in myopia (5 arms). Primary endpoint: Best Corrected Visual Acuity at 24 months. Started Feb 2024; status: recruiting.
02
Drugs
NVK002
03
Conditions
myopia
Beyond the preview
Go deeper on NCT06523504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06523504.